Ventures

DiaphOne TX is developing a first-in-class, orally available small-molecule therapy targeting the RAGE/DIAPH1 pathway, a central but underexploited disease axis in chronic metabolic and inflammatory conditions including type 2 diabetes, obesity and MASH. While existing treatments manage symptoms, they fail to address underlying disease progression. DiaphOne TX's approach targets the root of metabolic stress, inflammation and fibrosis, in a single platform with applicability across multiple high-value, multi-billion-euro markets.

Crainio pioneers intracranial pressure (ICP) monitoring, for assessing traumatic brain injuries (TBI) without invasive procedures. Traditional methods involve drilling into the skull, posing risks. Crainio's method uses a forehead probe and a technique called photoplethysmography to measure pulse signals. This gives real-time estimates of ICP without invasive procedures. With TBI being a leading cause of death and disability, Crainio's innovation will potentially revolutionize TBI management.

Respiosa offers a groundbreaking solution for obstructive sleep apnea (OSA), a condition affecting millions worldwide. Unlike traditional treatments like CPAP or surgery, Respiosa provides a minimally invasive, surgically implanted solution specifically targeting tongue-based obstruction, a common cause of OSA. Developed by Philips, Respiosa promises effective, durable, and adjustable therapy with a quick recovery time. With its natural and unobtrusive design, Respiosa ensures high patient adherence, addressing a significant gap in OSA treatment options.

Neurolieve Biosciences is developing NLV-01, a first-in-class, non-opioid treatment for peripheral neuropathy, addressing a market with over 500 million patients globally. Their GalR2 agonist delivers dual action that no current therapy offers: potent pain relief and nerve regeneration. Critically, NLV-01 does not cross the blood-brain barrier, eliminating the CNS side effects and addiction risk that limit opioids and gabapentinoids.

UltraTIL enables real-time tool-in-lesion confirmation during endobronchial lung cancer biopsies. This compact, side-viewing ultrasound probe is designed for the peripheral airways. UltraTil can be inserted through the working channel of a bronchoscope or robotic platform. By visualising lesions perpendicular to the airway and displaying the needle or biopsy instrument entering the target, UltraTIL improves the identification and sampling of small, eccentric and hard-to-reach lesions. The result: higher diagnostic accuracy, less reliance on additional positioning instruments, and shorter, more efficient procedures.

The challenge with lung cancer lies in its late detection, often leading to unfortunate outcomes. Current screening methods like low-dose CT scans are costly and have radiation risks, while blood tests lack accuracy or are too expensive. Our solution offers a non-invasive blood test that detects lung cancer early with high sensitivity and specificity. This test, with its multi-protein panel, can identify even stage I cancer, improving survival rates and reducing unnecessary procedures.

Flash Pathology revolutionizes tissue assessment with its scanner, with immediate imaging of biopsy and surgical specimens in the moment of operation. Unlike traditional methods, taking hours and requiring extensive labor, the Flash Pathology scanner visualizes cell structures within seconds without any preparation. This, non-labor-intensive solution enables distinguishing healthy tissue from tumors in real-time, reducing the need for revision surgeries and unnecessary biopsies.

PEP Health addresses the complexity of monitoring healthcare quality by offering a platform that tackles key challenges in quality assessment. By combining multiple sources of patient feedback, including social media, PEP provides near real-time assessments of quality for hospitals and departments. This approach reduces costs, improves timeliness, and enhances trustworthiness compared to traditional methods. With potential customers ranging from healthcare providers to patient organizations, PEP's underlying algorithm has been validated across industries, including higher education.